XENON PHARMACEUTICALS CFO Buys 7,500 Shares Amid Stock Slide, Signals Executive Confidence in Gene‑Therapy Pipeline
Insider buying shows CFO’s confidence in Xenon’s gene‑therapy pipeline amid market volatility, signaling long‑term upside potential.
3 minutes to read